NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

Enrolling By InvitationPhase 2

Sponsor: Massachusetts General Hospital

Conditions: Pseudohypoparathyroidism Type 1a, Obesity

Interventions: Setmelanotide

Countries: United States

The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Known patient with PHP1a (confirmed GNAS mutation)
* Optimized therapy for diabetes and dyslipidemia

Exclusion Criteria:

\- Use of medications that may affect endpoints that are changed within 3 months prior to Baseline or that are likely to require a change in dose during the open-label treatment period

Locations (1)

Boston, Massachusetts, United States